Price movement over the last 24 hours
Abbott Laboratories vs iShares MSCI Malaysia ETF — how do they compare? Abbott Laboratories trades at $95.21 (market cap $166.94B), while iShares MSCI Malaysia ETF trades at $27.28. The key difference: Abbott Laboratories pays a 2.63% dividend while iShares MSCI Malaysia ETF pays none, and iShares MSCI Malaysia ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | EWM | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $30.42 |
52-Week Low | $82.57 | $23.49 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
EWM, the iShares MSCI Malaysia ETF, trades at $27.24, up 1.0% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The ETF is heavily weighted in Financials (54%) and Industrials (21%), positioning it to benefit from Malaysia's data center expansion and tourism initiatives. A dividend of $0.57 is scheduled for payment on June 18, 2026.
Outlook is mixed: growth potential exists from Malaysia's economic initiatives, but bearish technicals and regional geopolitical risks from Middle East conflicts pose headwinds. Investors should weigh exposure to emerging market volatility against sector-specific opportunities in semiconductors and energy.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →